Leerink Partnrs Weighs in on Tourmaline Bio Q2 Earnings

Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Research analysts at Leerink Partnrs issued their Q2 2025 earnings estimates for Tourmaline Bio in a research note issued to investors on Monday, May 5th. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings per share of ($0.97) for the quarter. The consensus estimate for Tourmaline Bio's current full-year earnings is ($3.02) per share. Leerink Partnrs also issued estimates for Tourmaline Bio's Q3 2025 earnings at ($1.00) EPS and Q4 2025 earnings at ($0.96) EPS.

Other equities analysts have also issued research reports about the stock. HC Wainwright reissued a "buy" rating and issued a $50.00 price target on shares of Tourmaline Bio in a report on Monday. Chardan Capital reissued a "buy" rating and issued a $70.00 target price on shares of Tourmaline Bio in a research note on Monday. Lifesci Capital assumed coverage on Tourmaline Bio in a research note on Monday, February 24th. They set an "outperform" rating and a $58.00 price target for the company. Finally, Wedbush increased their price objective on Tourmaline Bio from $42.00 to $43.00 and gave the company an "outperform" rating in a research report on Friday, March 14th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $49.33.

Tourmaline Bio Trading Down 8.7 %

Shares of NASDAQ TRML opened at $14.54 on Wednesday. The business has a 50-day moving average of $15.32 and a 200-day moving average of $18.98. The firm has a market capitalization of $373.46 million, a price-to-earnings ratio of -5.16 and a beta of 2.11. Tourmaline Bio has a 12 month low of $11.56 and a 12 month high of $29.79.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) last announced its quarterly earnings results on Friday, May 2nd. The company reported ($0.89) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.91) by $0.02.

Institutional Investors Weigh In On Tourmaline Bio

A number of hedge funds and other institutional investors have recently modified their holdings of TRML. Vanguard Group Inc. increased its stake in Tourmaline Bio by 4.1% in the 4th quarter. Vanguard Group Inc. now owns 1,106,125 shares of the company's stock worth $22,432,000 after purchasing an additional 43,652 shares during the period. Adage Capital Partners GP L.L.C. bought a new stake in Tourmaline Bio during the 4th quarter valued at $12,168,000. Velan Capital Investment Management LP boosted its position in Tourmaline Bio by 28.0% during the 4th quarter. Velan Capital Investment Management LP now owns 423,795 shares of the company's stock valued at $8,595,000 after buying an additional 92,605 shares during the period. Pictet Asset Management Holding SA grew its holdings in Tourmaline Bio by 69.9% in the 4th quarter. Pictet Asset Management Holding SA now owns 419,883 shares of the company's stock worth $8,515,000 after acquiring an additional 172,743 shares during the last quarter. Finally, Acuta Capital Partners LLC increased its position in shares of Tourmaline Bio by 5.9% in the fourth quarter. Acuta Capital Partners LLC now owns 351,842 shares of the company's stock valued at $7,135,000 after acquiring an additional 19,747 shares during the period. Institutional investors own 91.89% of the company's stock.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.